openPR Logo
Press release

Scleroderma Therapeutics Market Analysis - Forecast to 2026

Scleroderma Therapeutics Market

Scleroderma Therapeutics Market

As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-scleroderma-therapeutics-market-3097

By Drug Class [Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others], By Indication [Systemic and Localized], By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
• Scleroderma is a chronic auto-immune condition with no clear cause. Fibrosis and microvascular damage in the infected organs are common symptoms.
• As per findings, this disorder is caused by changes in certain environmental parameters or variations in certain genes in humans.
• Systemic sclerosis, also known as scleroderma, is a progressive connective tissue condition that is treated as an autoimmune rheumatic disease.
• Increasing disposable income levels, allowing for greater buying potential, as well as key player expansions and FDA approval activities, are prepared to facilitate market growth.
• Increasing disposable income levels, allowing for greater buying potential, as well as key player expansions and FDA approval activities, are prepared to facilitate market growth.
• Generic and over-the-counter medications are the mainstay treatment for scleroderma and its effects in developed countries.
• F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex are the top players in the Scleroderma Therapeutics Market

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-scleroderma-therapeutics-market-3097

Drug Class Outlook (Revenue, USD Billion, 2021-2026)
• Immunosuppressors
• Phosphodiesterase 5 Inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Analgesics
• Others

Indication Outlook (Revenue, USD Billion, 2021-2026)
• Systemic
• Localized

Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
• The U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC
Central & South America
• Brazil
• Argentina
• Rest of CSA
Middle East & Africa
• Saudi Arabia
• UAE
• Rest of MEA

Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php

B-502, Kemp Plaza, Mindspace, Malad West, Mumbai: 400 064, India

Global Market Estimates is an India based market research and consulting company. The company provides syndicated research reports, customised research reports and consulting services to their clients and helps them achieve their business goals on a commercial level. Global Market Estimates database is used by the world's well known and prolific academic institutions and Fortune 500 companies to understand the global and regional business environment to excel in their business goals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Scleroderma Therapeutics Market Analysis - Forecast to 2026 here

News-ID: 2282835 • Views: 269

More Releases from Global Market Estimates Research & Consultants

Global Integrated Circuit Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Integrated Circuit Market is projected to grow at a CAGR value of 12.8% from 2022 to 2027. The growth of smartphone industry and related industries, development of semiconductor industry are other factors that will propel the integrated circuit market. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on "Global Integrated Circuit
Cell & Gene Therapy Raw Material Testing Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Cell & Gene Therapy Raw Material Testing Market is projected to grow from USD 13.1 billion in 2022 to USD 21.3 billion in 2027 at a CAGR of 17.3% from 2022 to 2027. Thermo Fisher Scientific, Merck KGaA, Catalent Inc., Charles River, Pace Analytical Life Sciences, Agilent Technologies, Intertek Group PLC, Element Material Technology, and Eurofins Scientific,
Global Single-use Upstream Bioprocessing Market
According to a new market research report published by Global Market Estimates, the Global Single-use Upstream Bioprocessing Market is projected to grow from USD 8.1 Billion in 2022 to USD 24.8 Billion by 2027 at a CAGR value of 15.5% from 2022 to 2027. Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, Corning Incorporated, Pall Corporation, General Electric Company (GE Healthcare), Eppendorf AG, Rentschler Biopharma SE, Lonza, Meissner
Global Car Rentals Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Car Rentals Market is projected to grow from USD 99.64 billion in 2022 to USD 139.65 billion by 2027 at a CAGR value of 5.4% from 2022 to 2027. The market for car rentals is expanding as a result of factors like the rising popularity of on-demand mobility services and millennials' low car ownership rates. Browse 153 Market

All 5 Releases


More Releases for Therapeutics

Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other